Baudax Bio (NASDAQ:BXRX) announces
the commercial launch of ANJESO (meloxicam) injection, indicated for
use in adults for the management of moderate-to-severe pain, alone or in
combination with non-NSAID analgesics.
The company has hired, trained, and now deployed
50 acute care sales representatives and that the Centers for Medicare
and Medicaid Services has approved transitional pass-through status and
established a new reimbursement code for ANJESO.
The code, C9059, is scheduled to become effective July 1.
https://seekingalpha.com/news/3582924-baudax-bio-launches-anjeso-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.